Duchenne muscular dystrophy (DMD) is characterised by progressive muscle weakness. It has recently been reported that single nucleotide polymorphisms (SNPs) located in the SPP1 and LTBP4 loci can account for some of the inter-individual variability observed in the clinical disease course. The validation of genetic association in large independent cohorts is a key process for rare diseases in order to qualify prognostic biomarkers and stratify patients in clinical trials.

Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants

SCOTTON, Chiara;PASSARELLI, Chiara;FERLINI, Alessandra;
2015

Abstract

Duchenne muscular dystrophy (DMD) is characterised by progressive muscle weakness. It has recently been reported that single nucleotide polymorphisms (SNPs) located in the SPP1 and LTBP4 loci can account for some of the inter-individual variability observed in the clinical disease course. The validation of genetic association in large independent cohorts is a key process for rare diseases in order to qualify prognostic biomarkers and stratify patients in clinical trials.
2015
van den Bergen, Janneke C; Hiller, Monika; Böhringer, Stefan; Vijfhuizen, Linda; Ginjaar, Hendrika B; Chaouch, Amina; Bushby, Kate; Straub, Volker; Sc...espandi
File in questo prodotto:
File Dimensione Formato  
J Neurol Neurosurg Psychiatry-2015-van den Bergen-1060-5.pdf

accesso aperto

Descrizione: versione editoriale
Tipologia: Full text (versione editoriale)
Licenza: Creative commons
Dimensione 651.51 kB
Formato Adobe PDF
651.51 kB Adobe PDF Visualizza/Apri

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2330844
Citazioni
  • ???jsp.display-item.citation.pmc??? 56
  • Scopus 74
  • ???jsp.display-item.citation.isi??? 69
social impact